sotatercept
Selected indexed studies
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. (N Engl J Med, 2023) [PMID:36877098]
- Sotatercept for the Treatment of Pulmonary Arterial Hypertension. (N Engl J Med, 2021) [PMID:33789009]
- Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. (N Engl J Med, 2025) [PMID:40167274]
_Worker-drafted node — pending editorial review._
Connections
sotatercept is a side effect of
Sources
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. (2023) pubmed
- Sotatercept for the Treatment of Pulmonary Arterial Hypertension. (2021) pubmed
- Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. (2025) pubmed
- Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. (2023) pubmed
- Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. (2025) pubmed
- Sotatercept. (2006) pubmed
- A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. (2025) pubmed
- Sotatercept: First Approval. (2024) pubmed
- Comparative Effectiveness of Sotatercept and Approved Add-On Pulmonary Arterial Hypertension Therapies: A Systematic Review and Network Meta-Analysis. (2024) pubmed
- Navigating the Sotatercept landscape: A meta-analysis of clinical outcomes. (2024) pubmed